

# 1 The mediating role of mammographic density in the protective effect of 2 early-life adiposity on breast cancer risk: a multivariable Mendelian 3 randomization study

4  
5 Marina Vabistsevi<sup>1,2\*</sup>, George Davey Smith<sup>1,2</sup>, Tom G. Richardson<sup>1,2</sup>, Rebecca C. Richmond<sup>1,2</sup>,  
6 Weiva Sieh<sup>3,4</sup>, Joseph H. Rothstein<sup>3,4</sup>, Laurel A. Habel<sup>5</sup>, Stacey E. Alexeeff<sup>5</sup>, Bethan Lloyd-Lewis<sup>6</sup>  
7 & Eleanor Sanderson<sup>1,2</sup>

8 1 - University of Bristol, MRC Integrative Epidemiology Unit, Bristol, United Kingdom,  
9 2 - University of Bristol, Population Health Sciences, Bristol, United Kingdom,  
10 3 - Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic  
11 Sciences, Department of Population Health Science and Policy, New York, NY, United  
12 States,  
13 4 - University of Texas MD Anderson Cancer Center, Department of Epidemiology, Houston,  
14 TX, United States,  
15 5 - Kaiser Permanente Northern California, Division of Research, Oakland, CA, United  
16 States,  
17 6 - University of Bristol, School of Cellular and Molecular Medicine, Bristol, United Kingdom

18

19 \* Corresponding author: Marina Vabistsevi<sup>1,2</sup>, MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol  
20 Medical School, University of Bristol, UK. E-mail: [marina.vabistsevi@bristol.ac.uk](mailto:marina.vabistsevi@bristol.ac.uk)

21

## 22 Abstract

23

24 Observational studies suggest that mammographic density (MD) may have a role in the unexplained  
25 protective effect of childhood adiposity on breast cancer risk. Here, we investigated a complex and  
26 interlinked relationship between puberty onset, adiposity, MD, and their effects on breast cancer using  
27 Mendelian randomization (MR).

28

29 We estimated the effects of childhood and adulthood adiposity, and age at menarche on MD  
30 phenotypes (dense area (DA), non-dense area (NDA), percent density (PD)) using MR and  
31 multivariable MR (MVMR), allowing us to disentangle their total and direct effects. Next, we examined  
32 the effect of MD on breast cancer risk, including risk of molecular subtypes, and accounting for genetic  
33 pleiotropy. Finally, we used MVMR to evaluate whether the protective effect of childhood adiposity on  
34 breast cancer was mediated by MD.

35

36 Childhood adiposity had a strong inverse effect on mammographic DA, while adulthood adiposity  
37 increased NDA. Later menarche had an effect of increasing DA and PD, but when accounting for  
38 childhood adiposity, this effect attenuated to the null. DA and PD had a risk-increasing effect on breast  
39 cancer across all subtypes. The MD single-nucleotide polymorphism (SNP) estimates were extremely  
40 heterogeneous, and examination of the SNPs suggested different mechanisms may be linking MD  
41 and breast cancer. Finally, MR mediation analysis estimated that 56% (95% CIs [32% - 79%]) of the  
42 childhood adiposity effect on breast cancer risk was mediated via DA.

43

44 In this work, we sought to disentangle the relationship between factors affecting MD and breast cancer.  
45 We showed that higher childhood adiposity decreases mammographic DA, which subsequently leads  
46 to reduced breast cancer risk. Understanding this mechanism is of great importance for identifying  
47 potential targets of intervention, since advocating weight gain in childhood would not be

48 recommended. This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 49 Introduction

50  
51 Breast cancer is the most common cancer in women worldwide [1]. Incidence rates continue to rise  
52 globally [2], and thus there is an urgent need to identify new and modifiable breast cancer risk factors.  
53 It is also critical to investigate the links between protective traits and breast cancer as those may reveal  
54 new mechanisms for targeted intervention. Observational and Mendelian randomization (MR) studies  
55 have shown that adiposity in childhood may reduce the risk of breast cancer in later life [3]–[7], and  
56 that this effect is direct and independent of adult body size. MR is an approach to causal inference  
57 that uses genetic variants as instrumental variables (IVs) to infer whether a modifiable health exposure  
58 influences a disease outcome [8] [9]. In previous work [10], we used an MR framework to investigate  
59 the biological mechanism underlying the protective effect of childhood adiposity by reviewing several  
60 potential mediators, including hormonal, reproductive, and glycaemic traits. However, none of the  
61 investigated mediators sufficiently explained the protective effect of childhood adiposity on breast  
62 cancer risk. A mediator that has not yet been thoroughly investigated is mammographic density (MD),  
63 an established risk factor for breast cancer [11], [12].

64  
65 MD refers to the radiological appearance of fibroglandular vs adipose tissue in the breast and is  
66 frequently quantified in three phenotypes: dense area (fibroglandular tissue, DA), non-dense area  
67 (adipose tissue, NDA) and percent density (dense area as a proportion of total breast size, PD). DA  
68 and PD are associated with an increased risk of breast cancer, whereas NDA is independently  
69 associated with a decreased risk [13]. A high DA and PD elevate breast cancer risk as tumours are  
70 more likely to arise in fibrous tissue, as well as being more difficult to detect in dense areas on a  
71 mammography exam [14]. MD is highly heritable [15] and the risk of developing cancer is 4-6 fold  
72 higher in women with extremely dense vs fatty breasts [14], but MD appears to be similarly associated  
73 with all breast cancer molecular subtypes [16], [17]. Although the association between MD and breast  
74 cancer is well-established, the molecular and cellular events that lead to the development of MD and  
75 why it is associated with increased cancer risk are not well understood [18].

76  
77 Growing evidence points to associations between childhood adiposity, puberty onset, and adult  
78 mammographic density (reviewed in [18]). Puberty is a critical time for breast development, during  
79 which the breast epithelial and stromal compartments undergo extensive growth and tissue  
80 remodelling [19]. Later age at menarche has been shown to positively associate with higher MD [20],  
81 [21], despite being associated with a decreased risk of breast cancer [22] [23]. Adiposity at different  
82 developmental stages also affects MD, as increased body size in adolescence is associated with a  
83 higher abundance of adipose non-dense tissue and lower dense area and percent density in adulthood  
84 [18], [20], [24], [25]. Childhood adiposity also has a well-established effect of decreasing age at  
85 menarche [26], which in turn leads to higher adult adiposity [27]. Taken together, these traits appear  
86 to have a complex and interlinked relationship that impacts breast development and growth, and  
87 ultimately breast cancer risk. Several recent observational studies have suggested that childhood  
88 adiposity may confer long-term protection against breast cancer via its effect on mammographic breast  
89 density [28]–[31]. The effect of MD on breast cancer has also been analysed using different MR  
90 methods [10], [32], [33]. While the overall picture reported from these studies supported  
91 observationally known associations, there were some differences depending on the MR method  
92 employed suggesting sensitivity to the underlying assumptions.

93  
94 Here, we explore the mediating role of mammographic density in the protective effect of high childhood  
95 adiposity on breast cancer risk, using data from genome-wide association study (GWAS) studies of  
96 childhood body size, adult body size, age at menarche, mammographic density, and breast cancer  
97 within a Mendelian randomization framework.

98  
99  
100  
101  
102  
103  
104  
105

## 106 Results

107

### 108 Study overview


109

110 In this study, we aimed to investigate the mediating role of mammographic density in the protective  
111 effect of childhood adiposity on breast cancer risk. Figure 1 presents a flow diagram of the  
112 relationships between the investigated traits. The summary of all analyses conducted is presented in  
113 Table 1. First, we examined the effect of body size (childhood and adulthood) on mammographic  
114 density (dense area, non-dense area, percent density) using univariable MR and multivariable MR  
115 (MVMR) [25]. We then reviewed the role of age at menarche in the childhood body size effect on MD  
116 phenotypes. Next, using data from the Breast Cancer Association Consortium (BCAC) [35][36]  
117 (Supplementary Table S1), we assessed the effect of MD phenotypes on breast cancer risk. We further  
118 investigated pleiotropy among the genetic instruments for the MD phenotypes using a variety of  
119 advanced sensitivity analysis methods [37]–[39], PheWAS [40], and pathway analysis, to dissect their  
120 heterogeneous effect and improve the understanding of the MD effect on breast cancer. Finally, we  
121 performed MVMR of childhood body size and MD phenotypes with breast cancer risk and mediation  
122 analysis to assess the direct and indirect effects of both traits and evaluate the role of MD in the poorly  
123 understood protective effect of childhood body size on breast cancer.

124

125 This study is reported as per the guidelines for strengthening the reporting of Mendelian randomization  
126 studies (STROBE-MR) [41] [42].

127



128

129

130 **Figure 1. Flow diagram of relationships between traits investigated in this study.** Blue arrows indicate a negative  
131 (decreasing / protective) effect and pink arrows show a positive (increasing / causal) effect relationship, as previously  
132 reported in the literature. The numbers signpost the analysis sections, which are mentioned throughout the text and  
133 correspond to the numbers in the analysis summary in Table 1.

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149 **Table 1. Summary of analyses conducted.** The table is split into sections (#) for convenient reference throughout the  
 150 text. Mammographic density (MD) is available as three phenotypes: Dense area (DA), non-dense area (NDA), and  
 151 percent density (PD); data source: Sieh *et al* (2020) [32]. Breast cancer outcomes include data from BCAC 2017 and  
 152 2020 (overall samples, ER+/ER- samples and five molecular subtypes: Luminal A, Luminal B1, Luminal B2, HER2-  
 153 enriched, and triple-negative; summarised in Supplementary Table S1; data sources: [35][36]). Childhood/adult size  
 154 body and age at menarche data are UK Biobank phenotypes from Richardson *et al* (2020) [5]. In the table, when several  
 155 exposures/outcomes are listed (e.g. MD phenotypes or cancer subtypes), this indicates that MR analysis was done  
 156 separately for each, unless they are two exposures in MVMR. MR – Mendelian randomization, MVMR – multivariable  
 157 MR, BCAC – Breast Cancer Association Consortium  
 158

#	Analysis type	Exposure trait(s) represented as genetic instruments	Phenotypic outcome traits(s) (when applicable)	Results available in
1	MR	Childhood body size	Mammographic density (DA, NDA, PD)	Figure 2a, Table S3
	MR	Adult body size	Mammographic density (DA, NDA, PD)	
	MVMR	Childhood body size, Adult body size	Mammographic density (DA, NDA, PD)	Figure 2b, Table S5
2	MR	Age at menarche	Mammographic density (DA, NDA, PD)	Figure 2a, Table S7
	MVMR	Childhood body size, age at menarche	Mammographic density (DA, NDA, PD)	Figure 2c Table S9
3	MR	Dense area (DA)	Breast cancer (overall and subtypes)	Figure 3a, Table S11
	MR	Non-dense area (NDA)	Breast cancer (overall and subtypes)	
	MR	Percent density (PD)	Breast cancer (overall and subtypes)	
4	MVMR	Childhood body size, Dense area (DA)	Breast cancer (overall and subtypes)	Figure 3b, Table S13
	MVMR	Childhood body size, Non-dense area (NDA)	Breast cancer (overall and subtypes)	
	MVMR	Childhood body size, Percent density (PD)	Breast cancer (overall and subtypes)	
5	MR-PRESSO	Mammographic density (DA, NDA, PD)	Breast cancer overall sample	Figures 4a, S4a, S6a Table S16
	Radial-MR	Mammographic density (DA, NDA, PD)	Breast cancer overall sample	Figures 4b, S4b, S6b Table S17
	MR-Clust	Mammographic density (DA, NDA, PD)	Breast cancer overall sample	Figures 4c-d, S4c-d, S6c-d Table S18
6	PheWAS	Mammographic density (DA, NDA, PD)	N/A	Figure 5, S5, S7 Tables S19-S21
7	Pathway analysis	Mammographic density (DA, NDA, PD)	N/A	Tables S22-27
8	Mediation analysis	Childhood body size, Dense area (DA) (as a mediator)	Breast cancer overall sample	Supplementary Note 2


159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174

## The effect of childhood and adult body size on mammographic density

We used univariable MR to evaluate the total effect of childhood and adult body sizes on each MD phenotype (analysis #1 in Table 1 and Figure 1). This analysis was performed using MD GWAS data unadjusted for adult BMI to avoid double adjustment for BMI in MVMR analyses; the details of this and subsequent analyses using MD GWAS data adjusted for adult BMI (i.e. the data from the original publication of MD GWAS [32]) are available in Supplementary Note 1. We found evidence that larger body size, both during childhood and as an adult, reduces dense area and percent density, but increases non-dense area (Figure 2a, Supplementary Table S3). The estimates from these analyses reflect the standard deviation (SD) change in MD phenotype for each change in childhood and adult body size category. We also performed multivariable MR including both childhood and adult body size to estimate the direct effects of body size at each age on MD conditional on the other age (Figure 2b, Supplementary Table S5). In this analysis, a direct effect was demonstrated for both traits,

175 however, larger childhood body size had a stronger effect on decreasing dense area, while larger  
176 adult body size had a stronger effect on increasing non-dense area (adipose tissue area of the  
177 breast). The direct effect on percent density was greater from adult body size, but its magnitude was  
178 considerably reduced in MVMR for both measures.

179  
180



181  
182

183 **Figure 2. Univariable MR (total effect) and multivariable MR (direct effect) results of childhood body size, adult body size, and age at menarche effect on MD phenotypes (dense area, non-dense area, percent density) (unadjusted for BMI at GWAS level).** (a) Total effect of each exposure on MD outcomes. (b) Direct effects of childhood and adult body sizes on MD outcomes. (c) Direct effects of childhood body size and age at menarche on MD outcomes. The effect is measured as the standard deviation (SD) change in MD phenotype per body size category or age at menarche SD change. Bars indicate 95% confidence intervals around the point estimates from MR/MVMR IVW analyses. The empty circle data points highlight the results where confidence intervals overlap the null.

189  
190  
191

## 192 The effect of childhood body size and age at menarche on mammographic density

193

194 In this MR analysis, we sought to analyse childhood body size and age at menarche together to  
195 evaluate their total and direct effects on MD phenotypes (analysis #2 in Table 1 and Figure 1). In  
196 univariable MR (Figure 2a, Supplementary Table S7), childhood body size and age at menarche had  
197 strong opposing effects on MD (DA and PD), which is in agreement with published studies [20] [21],  
198 [25]. In MVMR (Figure 2c, Supplementary Table S9) the direct effect of body size conditional on age  
199 at menarche is similar to the total effect, while the effect of age at menarche is attenuated to overlap  
200 the null. Adiposity in childhood reduces MD and lowers the age at menarche (as shown in [10]), while  
201 younger age at menarche has a negative effect on MD (i.e. the inverse of higher age at menarche  
202 increasing MD in Figure 2a). The attenuation of age at menarche effect can be explained in the  
203 following way: (1) the direct effect of childhood adiposity is maintained in MVMR when accounting  
204 for age at menarche, suggesting that adiposity affects MD independently of starting puberty earlier,  
205 (2) the menarche effect in univariable results is not present in MVMR results suggesting that it is  
206 largely due to unaccounted increased childhood adiposity (and its effect on the initiation of puberty).  
207 Collectively, our results show that the density-decreasing effect of larger childhood body size is not  
208 acting via lowering the age at menarche, and that childhood body size and age at menarche may  
209 have entirely different mechanisms linking them to breast cancer.

210  
211


## 212 The effect of mammographic density on breast cancer

213

214 Next, we evaluated the effect of BMI-unadjusted MD phenotypes on breast cancer (analysis #3 in  
215 Table 1 and Figure 1) using IVW MR estimation. The total effect of MD phenotypes on breast cancer  
216 subtypes is presented in Figure 3a (Supplementary Table S11). Overall, we found a consistent trend  
217 in the direction of effect across all breast cancer subtypes for each MD exposure trait: dense area  
218 and percent density increased the risk, while non-dense area decreased the risk, which is in line with  
219 the observational data. Despite being consistent, many estimates were imprecise, however, there  
220 was stronger evidence for a positive effect of dense area on overall breast cancer, ER+ breast  
221 cancer, and several subtypes. The individual SNP-specific effects within all MD phenotypes' total  
222 estimates were heterogeneous (detailed below under **Sensitivity analysis**), and therefore, in the



223 **Dissecting the mammographic density effect using robust MR methods** section we explore  
224 those effects using various sensitivity and outlier detection methods. The direct effects from the  
225 MVMR analysis in Figure 3b are discussed in a later section.  
226



227  
228  
229 **Figure 3. (a) The total (univariable MR) and (b) direct (accounted for childhood body size, MVMR) effect of**  
230 **MD phenotypes (unadjusted for BMI) on breast cancer (overall sample from BCAC 2017 and subtype**  
231 **samples).** The plots show the odds of breast cancer per SD increment in MD phenotype. Bars indicate 95%  
232 confidence intervals around the point estimates from IVW and IVW-MVMR analyses. The empty circle data points  
233 highlight the results where confidence intervals overlap the null.  
234

### 235 236 237 **Sensitivity analysis** 238

239 To investigate potential violations of the MR assumptions and validate the robustness of the two-  
240 sample IVW MR results, we performed additional MR analyses using MR-Egger [43] and weighted  
241 median [44] approaches, both of which provide sensitivity analyses that are more robust to particular  
242 forms of horizontal pleiotropy. The Egger intercept was used to explore the potential for the presence  
243 of directional horizontal pleiotropy, and Cochran's Q statistic [45] was calculated to quantify the  
244 extent of heterogeneity among SNPs, which is indicative of potential pleiotropy. For MVMR we tested  
245 instrument strength, using a conditional F-statistic [46] and examined heterogeneity using an  
246 adapted version of the Q-statistic ( $Q_A$ ).  
247

248 The estimated total effects of childhood and adult body size measures on MD phenotypes were  
249 consistent across MR sensitivity analyses with Egger intercept 0.01 or lower. The F-statistics were  
250  $> 10$  and Q-statistics did not indicate excessive heterogeneity (Supplementary Table S4). In MVMR,  
251 the conditional F-statistics were also above 10, indicating that weak instrument bias is unlikely to be  
252 present [46]. The presence of directional pleiotropy was assessed by estimating  $Q_A$  statistics, which  
253 also were not notably large (Supplementary Table S6).  
254

255 The direction of effect was consistent among the MR methods when assessing age at menarche  
256 effect on MD phenotypes, but there was less robust evidence of effect in the weighted median result.  
257 The F-statistic for age at menarche was above 10; the Egger intercept was substantially close to  
258 zero ( $\sim 0.002$ ), indicating little evidence of directional pleiotropy [47]. The Cochran's Q value was  
259 large with p-values  $< 2e-10$ , indicating high heterogeneity (Supplementary Table S8). In MVMR of  
260 age at menarche and childhood body size, the F-statistics were above 10, and  $Q_A$  was similar to the  
261 Q value in the univariable analysis (Supplementary Table S10).  
262

263 In the main IVW analysis of MD phenotypes effect on breast cancer outcomes, the evidence was  
264 present only in selected exposure-outcome pairs, as described in the previous section. Applying  
265 sensitivity methods to those results showed some inconsistency, with MR-Egger producing imprecise  
266 results. The weighted median approach, which relies on at least 50% of the variants' total weight  
267 being from valid instruments [44], provided evidence for an effect in substantially more analyses than  
268 IVW, which relies on 100% of variants being valid instruments, indicating that some variants may be  
269 outliers (Supplementary Table S11). The Egger intercept in the analyses of non-dense area and  
270 percent density with subtype outcomes suggested likely presence of horizontal pleiotropy. The  
271 intercept in analyses of dense area, where evidence of effect was present in IVW, was smaller,  
272 indicating that dense area phenotype is less subject to pleiotropy. The MD phenotypes' instrument  
273 strength was good (F-statistics > 10) suggesting that weak instruments are unlikely to be a source  
274 of serious bias in the univariable analysis. Steiger filtering did not indicate that MD phenotypes'  
275 instruments explained more variance ( $R^2$ ) in breast cancer rather than in MD phenotypes, and  
276 therefore, were not excluded from the analysis. Interestingly, we identified substantial heterogeneity  
277 for all MD phenotypes, suggested by very high Q-values with small p-values. High heterogeneity  
278 may be indicative of one or more variant outliers in the analysis, which was explored with additional  
279 sensitivity in the next section. The sensitivity analysis details are available in Supplementary Table  
280 S12.

281

## 282 **Dissecting the mammographic density effect using robust MR methods**

283

284 To explore the high heterogeneity in the genetic instruments for the MD phenotypes, we applied  
285 several methods that aim to dissect heterogeneity and assess potential horizontal pleiotropy through  
286 outlier detection (analysis #5 in Table 1). In this investigation, we focused only on the overall breast  
287 cancer sample outcome.

288

289 We used MR-PRESSO [37] and Radial-MR [39] (see **Methods**) to identify the variant outliers  
290 (Supplementary Tables S16-17). For dense area, both methods determined the same set of SNPs  
291 as outliers (Figures 4a and 4b). The outlier-corrected total IVW estimates are presented below the  
292 single SNP forest plots (outlier SNPs are highlighted), alongside the results of other MR methods.  
293 With outliers removed, the point estimate (OR 1.40 [1.26: 1.56]) is similar to the original IVW result  
294 (OR 1.38 [1.002: 1.90]), but the confidence intervals are more precise. Consequently, the outlier-  
295 corrected IVW estimates of dense area had stronger evidence of effect on breast cancer, and were  
296 similar to weighted median method results (OR 1.25 [1.12: 1.39]).


297

298 Next, we used MR-Clust [38] to investigate the presence of clustered heterogeneity among the  
299 genetic variants. MR-Clust groups genetic variants into clusters with similar estimates for the causal  
300 effect of the exposure on the outcome (i.e. based on their direction, magnitude, and precision). A  
301 cluster may represent a distinct pathway through which exposure is related to the outcome, and  
302 investigating heterogeneous estimates in this way may reveal additional information about the  
303 exposure-outcome relationship (see **Methods** for further details). MR-Clust detected three distinct  
304 clusters ('cluster\_1', 'cluster\_2', 'cluster\_3'), a 'null' cluster, and two 'junk' SNPs that were not  
305 assigned to any of the clusters (Figure 4c, Supplementary Table S18). We see that the heterogeneity  
306 outliers flagged by MR-PRESSO and Radial-MR (Figures 4a and 4b) represent separate clusters in  
307 MR-Clust (Figure 4d). 'Cluster\_2' (blue) is equivalent to the outlier-corrected estimate from those  
308 earlier analyses and the variants in this cluster are positively associated with an increase in both  
309 dense area and breast cancer risk. 'Cluster\_3' (orange) and a positive 'junk' SNP are associated  
310 with breast cancer to a higher magnitude (Figure 4c) and therefore form a separate cluster.  
311 Interestingly, the SNPs in 'cluster\_1' are protective of breast cancer despite being associated with  
312 increased density. It is important to note that both the inverse association ('cluster\_1') and the same  
313 direction but higher magnitude association ('cluster\_3') clusters add to the overall heterogeneity of  
314 the total estimate.

315

316 The results for non-dense area and percent density phenotypes are presented in Supplementary  
317 Figures S4 and S6. We similarly found outliers and clusters in those traits' instruments. However,  
318 due to the lower number of instruments available for these traits, the results from MR-PRESSO and  
319 Radial-MR should not be overinterpreted. The outlier-corrected IVW estimates (non-dense area –

320 OR 0.75 [0.65: 0.86] and percent density – OR 1.29 [1.16: 1.44]) were similar to the weighted median  
 321 method results (OR 0.74 [0.63: 0.87] and OR 1.32 [1.14: 1.53], respectively) (Supplementary Tables  
 322 S16 and S17). In MR-Clust, for non-dense area and percent density, there were also variants that  
 323 associated with breast cancer in the opposite direction to the overall and expected effect from the  
 324 exposure (e.g. negatively associated with breast cancer risk but positively associated with a factor  
 325 causal for breast cancer, or vice versa) – two ‘negative effect’ outliers for percent density and one  
 326 ‘positive effect’ outlier for non-dense area).  
 327  
 328



329  
 330 **Figure 4. Exploring the heterogeneity of genetic instruments of dense area phenotype on overall breast**  
 331 **cancer (BCAC 2017). (a)** Single SNP forest plot (Wald Ratio estimates), with SNPs identified as outliers by MR-  
 332 PRESSO marked in blue. The outlier corrected estimate is presented along with the standard MR methods estimates.  
 333 **(b)** Single SNP forest plot with SNPs identified as outliers by Radial-MR marked in yellow. The outlier corrected  
 334 estimate is presented along with the standard MR methods estimates. **(c)** MR-Clust scatter plot showing genetic  
 335 association with dense area and breast cancer per SD change in dense area. Each genetic variant is represented by  
 336 a point. Error bars are 95% confidence intervals of the Wald Ratio for each variant. Colours represent the clusters,  
 337 and dotted lines represent the cluster means, the point size denotes cluster inclusion probability. The “null” cluster,  
 338 coloured pink, relates to variants with null effect, whilst the black “junk” cluster are variants that were not assigned to  
 339 any cluster. The error bars denote the standard error estimates of the Wald Ratio for each instrumental variable. **(d)**  
 340 Single SNP forest plot with SNPs coloured by the cluster membership assigned by MR-Clust (using the same colours  
 341 as in the scatter plot). The IVW MR estimates for each cluster are presented below single SNP estimates. IVW –  
 342 inverse-variance weighted; MRE – multiplicative random effects



## 343 PheWAS

344

345 We carried out a phenome-wide association study (PheWAS) analysis [40] on the genetic  
346 instruments for the MD phenotypes to examine their associations with other traits (analysis #6 in  
347 Table 1). We aimed to review the differences between associations by clusters identified with MR-  
348 Clust and evaluate whether outlier SNPs may be strongly associated with other phenotypes, which  
349 may explain the horizontal pleiotropic effect and hint at alternative causal pathways for those outliers.


350

351 The PheWAS results for the dense area phenotype are plotted in Figure 5. The SNPs that were  
352 identified as outliers in previous analyses and that formed distinct clusters from the main effect  
353 clusters, have a higher number of associations with other traits, highlighting their pleiotropic effect.  
354 In the plot, we use the diamond shape to indicate dense area SNPs that associate strongly ( $p$ -value  
355  $< 5e-08$ ) with breast cancer. Those SNPs correspond to 'cluster\_3', 'cluster\_1', and 'junk' cluster  
356 SNPs in the MR-Clust results, here similarly flagging their association with breast cancer risk, which  
357 may be happening via a different pathway other than through dense area.

358

359 PheWAS plots for non-dense area and percent density are available in Supplementary Figures S5  
360 and S7. For those phenotypes, similarly, we found associations with breast cancer for the outlier  
361 SNPs. All found associations are available in Supplementary Tables S19-21.

362



363

364 **Figure 5. PheWAS results for dense area phenotype genetic variants, ordered by SNP effect and cluster**  
365 **membership** (from MR-Clust). The data points are other traits associated with dense area SNPs (y-axis) at  $p$ -value  
366  $< 5e-08$  (x-axis,  $-\log_{10}$  scale, capped at value 50). The colour shows the cluster membership, in the same palette  
367 and order as in Figures 4c/4d. Data points represented by solid 'diamond' shapes are breast cancer outcomes;  
368 'plus' shapes are all other traits.

369

370

## 371 Gene and pathway overview

372

373 To gain some biological context for the identified outlier SNPs and distinct clusters, we mapped  
374 instrument SNPs to genes (Supplementary Tables S22-24; see gene-labelled forest plots in  
375 Supplementary Figure 8) and identified pathways that those genes are involved in (analysis #7 in  
376 Table 1). Performing a formal gene-set enrichment analysis was not possible here due to the limited  
377 number of SNPs available for each phenotype/cluster. Therefore, instead, we created a simple  
378 overview of pathway sets that came up for genes in positive and negative effect clusters  
379 (Supplementary Table S25-27, Supplementary Figure 9).

380

381 For dense area, we found a number of unique pathways that only appeared in genes/SNPs with a  
382 negative effect. Among those genes, most were described in the functional analyses of previously  
383 published MD GWAS [48], [49], [32], such as *MKL1/MRTFA* (rs73169097 – negative 'null' cluster  
384 SNP) and *MTMR11* (rs11205303), both of which have dense phenotype-increasing effect but are  
385 protective against breast cancer. The potential tumour-inhibiting and tumour-promoting role of *MKL1*

386 was previously acknowledged in [48]. *MTMR11* is negatively associated with both dense area and  
387 percent density (but as a result of LD clumping it is an instrument only for dense area). It appears to  
388 be involved in phosphoinositides/phosphatidylinositol metabolism pathways, which are also  
389 implicated in cancer. For percent density, the genes in negative clusters were also previously  
390 described in published functional analyses - *OTUD7B* (rs12048493) and *ZNF703* (rs4286946) [49],  
391 [50]. Interestingly, the positive outlier in non-dense area instruments is also mapped to *ZNF703*  
392 (rs75772194), which is also associated with breast size. The complete overview of  
393 cluster/genes/pathways is available in Supplementary Tables S25-27.

394

395

### 396 **The direct effect of mammographic density and childhood body size on breast cancer** 397 **risk**

398

399 In the earlier sections, we reviewed the total effect of MD phenotypes on breast cancer risk (Figure  
400 3a) and explored it using various sensitivity analyses. In this section, we dissect the direct effects of  
401 childhood body size and MD phenotypes on breast cancer risk using MVMR (analysis #4 in Table 1  
402 and Figure 1). In Figure 3b (Supplementary Table S13), we see the direct effect of MD on breast  
403 cancer accounting for childhood body size, presented alongside the total effect for comparison.  
404 There is evidence of a positive direct effect from the dense area on all breast cancer subtypes. The  
405 point estimates are similar to those of the total effect, but with more precise confidence intervals.  
406 There is evidence of a negative effect from non-dense area on Luminal B1 and triple-negative  
407 subtypes, while the effects on other samples have been further attenuated towards the null. For  
408 percent density, the magnitude of effect and the uncertainty around the point estimate is reduced in  
409 MVMR analysis, with little evidence for an effect of PD on all breast cancer subtypes when  
410 accounting for childhood body size. It should be noted that IVW MVMR estimates may also be  
411 potentially biased by pleiotropy in the same way as total effect estimates in univariable MR.

412

413 From the same MVMR analysis as the results in Figure 3b, we have also estimated the direct effect  
414 of childhood body size on breast cancer accounted for MD phenotypes. Figure 6 presents the total  
415 effect of childhood body size on breast cancer (overall and subtypes) (Supplementary Table S15)  
416 along with the direct effect accounted for each MD phenotype (Supplementary Table S13). The total  
417 effect is strongly protective against all outcomes. In previous work, this protective effect was not  
418 disrupted by accounting for any hypothesised mediators [10]. In this analysis, we see that accounting  
419 for MD phenotypes attenuates the protective effect making the confidence intervals overlap the null,  
420 suggesting that MD may have a role in partially explaining it. When accounting for the dense area,  
421 the effect attenuation is seen for all outcomes except the ER- sample. For percent density, the effect  
422 on breast subtypes is attenuated but to a lesser extent, which may suggest that dense area  
423 phenotype has a stronger mediating role than percent density. For non-dense area, the effect is  
424 attenuated also on a subset of breast cancer subtypes. Interestingly, the effect on ER- subtype is  
425 the least affected, suggesting there might be some difference in how MD affects ER- breast cancer  
426 risk.


427

428 It is important to note that the number of MD instruments in this MVMR analysis was limited  
429 (Supplementary Table S2). These MVMR results are also affected by weak instrument bias, as F-  
430 statistics are low in these analyses: childhood body size and dense area (F-stat, 17 and 7,  
431 respectively) non-dense area (6 and 3), percent density (7 and 4), respectively (Supplementary Table  
432 S14).

433

434

435



436  
 437 **Figure 6. The total and direct effects of childhood body size (accounted for MD phenotypes – dense area,**  
 438 **non-dense area, percent density (unadjusted for BMI at GWAS level)) on breast cancer (overall sample from**  
 439 **BCAC 2017 and subtype samples).** The plots show the odds of breast cancer per body size category change. Bars  
 440 indicate 95% confidence intervals around the point estimates from IVW and IVW-MVMR analyses. The empty circle  
 441 data points highlight the results where confidence intervals overlap the null.

442  
 443  
 444 **Mediation analysis**

445  
 446 We performed mediation analysis using MR and MVMR results to assess the role of mammographic  
 447 density (specifically, dense area) in the relationship between childhood body size and breast cancer.  
 448 This investigation was also done focussing only on the overall breast cancer sample (analysis #8 in  
 449 Table 1).

450  
 451 We estimated the indirect effect via MD, using both Product and Difference methods for mediation  
 452 analysis (see **Methods**). Both methods produced similar indirect point estimates in the same  
 453 direction, -0.23 [95% CIs; -0.33: -0.13] and -0.22 [-0.48: 0:05], respectively. The proportion of the  
 454 mediated effect via dense area using the Product method estimate was 0.56, indicating that dense  
 455 area may account for 56% [32%-79%] of the childhood body size protective effect on breast cancer  
 456 (see **Supplementary Note 2** for mediation analysis calculations).

457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468

## 469 Discussion

470

471 The protective effect of higher childhood adiposity on breast cancer risk has been reported in both  
472 observational and MR studies [3]–[7]. However, the mechanism behind this effect has been  
473 challenging to decipher, even after reviewing nearly 20 potential mediators [10]. A few observational  
474 studies have suggested that mammographic density may have a role in this relationship [28]–[31].  
475 In this study, we explored the mediating role of MD in the protective effect of higher childhood  
476 adiposity on breast cancer risk using Mendelian randomization, examining the complex relationships  
477 between childhood body size, adult body size, age at menarche, mammographic density, and breast  
478 cancer risk.

479

480 Firstly, we investigated the factors that may affect MD – adiposity at different life stages and age at  
481 menarche. We found that higher childhood and higher adulthood adiposity decrease dense area and  
482 percent density, while both increase the non-dense (adipose tissue) area. In multivariable MR  
483 analysis, however, the independent direct effect of childhood adiposity was stronger for decreasing  
484 dense area, while adult adiposity was stronger for increasing non-dense area. The inverse effect of  
485 higher body size on density is likely explained by increasing breast adiposity, reducing the proportion  
486 of fibroglandular components, and increasing adipocyte differentiation of stromal cells, thus reducing  
487 collagen production [51]. As breast tissue undergoes substantial development during puberty, it is  
488 reasonable that childhood rather than adult adiposity is a more important factor for dense area. The  
489 stronger effect of adult adiposity on the non-dense area is likewise logical, as the change in MD with  
490 age is reflected in glandular tissue reduction and an increase in fat [52]. We also showed that  
491 adjustment for BMI in GWAS may lead to an unexpected and misleading result in MR analysis  
492 (Supplementary Note 1), if BMI (i.e. heritable covariate) also has a role in the studied relationship  
493 [53] [54].

494

495 The previously observed association of age at menarche with breast density [20] was replicated in  
496 our MR analysis, with later menarche increasing dense area and percent density and decreasing  
497 non-dense area. In MVMR with childhood body size, however, the effect of age at menarche on MD  
498 phenotypes was attenuated. Greater adiposity in childhood reduces dense area and percent density  
499 and lowers the age at menarche [10], while earlier menarche decreases dense area and percent  
500 density. Therefore, the attenuation of its effect in MVMR indicates that the menarche effect observed  
501 in the univariable analysis may be due in part to increased adiposity (and its effect on the initiation  
502 of puberty). Collectively, our results suggest that the density-decreasing effect of childhood body size  
503 is not acting predominantly via lowering the age at menarche.

504

505 This finding draws attention to prior MR studies showing little evidence of effect of age at menarche  
506 on breast cancer risk [10], [55]. Interestingly, in MVMR analyses when accounting for BMI, there is  
507 a shift from the neutral effect to a causal effect with earlier age at menarche increasing the risk. It  
508 is likely that the total effect of age at menarche is driven (and disguised) by childhood BMI SNPs  
509 in the age at menarche GWAS instruments, and accounting for BMI in MVMR separates the  
510 independent effects of childhood BMI and age at menarche on breast cancer risk. Taken together  
511 with our finding that MD is not affected by age at menarche when accounting for body size, this  
512 suggests that the mechanisms linking childhood adiposity and age at menarche to breast cancer  
513 could be entirely different and operate in opposite directions. Uncovering the mechanistic links in  
514 both relationships (as partly done in this work with respect to childhood body size) will identify  
515 different pathways that could be modifiable, and together could contribute a very substantial  
516 component of modifiable breast cancer risk. Another important consideration relating to  
517 mechanistic links is the distinction between mutagenesis and promoters in breast cancer causation  
518 [56], which may also contribute to the differential effects of childhood adiposity and age at  
519 menarche on breast cancer risk.

520

521 The central relationship explored in our study is that of MD and breast cancer, and whether MD helps  
522 explain the inverse association of childhood adiposity and breast cancer risk. When examining the  
523 total effect of MD phenotypes on breast cancer risk (overall and subtypes), we observed consistent  
524 trends in the direction of effects, with dense area and percent density increasing the risk and non-  
525 dense area decreasing the risk, in line with observational results [12][13]. We found evidence of a

526 positive effect from the dense area on breast cancer risk overall and for certain subtypes, but for  
527 other MD exposure/breast cancer outcome pairs the evidence was insufficient. The results produced  
528 by the IVW method may potentially be biased by pleiotropy, therefore the detected high levels of  
529 heterogeneity were further explored in our analysis and will be discussed below. It is also worth  
530 mentioning that our results may slightly differ from the previously published MR results using related  
531 data [10], [32], [33], which could be explained by the differences in the MR methods employed, the  
532 approach to instrument selection, and the fact that the MD GWAS was unadjusted for BMI in this  
533 study.

534  
535 While the total effect of MD on breast cancer was imprecisely estimated, IVW-MVMR of MD  
536 phenotypes with childhood body size showed strong evidence of a risk-increasing direct effect from  
537 the dense area on all breast cancer subtypes, with less evidence for a negative effect of non-dense  
538 area and a lack of evidence for an effect of percent density. This highlighted the possibility that dense  
539 area is the more important risk factor for breast cancer, however in observational studies [12],  
540 percent density has been found to have a stronger association because it combines the effects of  
541 both dense area and non-dense area which have distinct genetic aetiologies [32]. The direct effect  
542 of childhood body size on breast cancer was attenuated in this MVMR analysis, suggesting a  
543 potential mediating role of mammographic density in the relationship between them. This is the first  
544 time we have observed an attenuation of the effect of childhood body size; in our previous work,  
545 where many potential mediations were assessed, the body size effect remained unaffected [10].  
546 Interestingly, this attenuation of effect was not present in analyses of ER-negative breast cancer,  
547 suggesting that there might be some differences in how MD affects this disease subtype. We  
548 considered including adult body size and age at menarche as covariates in MVMR, however, we  
549 opted not to pursue this analysis due to concerns about the statistical power.

550  
551 In addition to the effect changes observed in MVMR, we conducted a formal mediation analysis with  
552 the dense area phenotype. Both mediation methods we applied produced very similar indirect effect  
553 estimates (-0.23 and -0.22, Product and Difference methods, respectively). Such agreement of  
554 estimates was not the case for other mediators we reviewed in our previous work [10]. The  
555 confidence intervals around these estimates were more precise for the Product method -0.23 [-0.33:  
556 -0.13]). The calculated proportion mediated via dense area suggested that 56% [32%-79%] of  
557 childhood adiposity's protective effect could be due to it decreasing the dense area in childhood,  
558 which leads to reduced breast cancer risk in adulthood.

559  
560 The above finding is promising, however, the relationship of MD phenotypes with breast cancer is  
561 complex and, as shown in our sensitivity analyses, the genetic variants used in the analysis have  
562 heterogeneous estimates and are potentially highly pleiotropic. We thoroughly evaluated the dense  
563 area, non-dense area, and percent density genetic instruments using several robust MR outlier  
564 detection methods and an MR clustering method, MR-Clust, to decompose heterogeneity in the  
565 results. For dense area and percent density, we found a set of outlier SNPs that together formed  
566 'negative effect' clusters, which mapped to genes that were associated with higher dense  
567 area/percent density, but a decreased cancer risk. This has been previously reported for the same  
568 identified genes, e.g. *MLK1* in [48] and *MTMR11* in [49]. Similarly, for the non-dense area, we found  
569 one SNP with the opposite effect on breast cancer to the overall effect direction. The PheWAS  
570 analysis highlighted the fact that outlier SNPs, which also form separate clusters of MD effect on  
571 breast cancer, were highly pleiotropic, with the majority also associated with breast cancer. Several  
572 methods for outlier correction showed that removing those SNPs results in stronger and more  
573 consistent effects of MD phenotypes on breast cancer risk.

574  
575 The discovery of multiple MD variants that are also breast cancer susceptibility loci, highlights their  
576 shared genetic component and the critical role MD plays as an intermediate phenotype for the  
577 disease. The inconsistency in the direction of associations between some MD-associated SNPs and  
578 breast cancer risk is perplexing, and is the reason for the observed heterogeneity in MR estimates.  
579 One potential explanation for discrepancies in these variants may be that multiple alternative  
580 pathways are involved, and are acting across different life stages, which differentially affect breast  
581 development and the risk of breast cancer. There is also a strong possibility that not all contributors  
582 to MD influence breast cancer risk. Understanding, and correctly classifying the driving components



583 of MD (reviewed in [57]) into those that influence breast cancer risk, and using those for future studies  
584 could increase results precision and the degree of mediation detected. Motivated by a recent study  
585 that explored a similarly heterogenous effect of IGF-1 on type 2 diabetes using MR-Clust and  
586 pathway analysis [58], in our work, we attempted to characterise pathways that may be underlying  
587 the identified positive and negative effect clusters. In our case, however, due to the limited number  
588 of instruments, pathway gene-set enrichment analysis was not feasible. An extensive pathway  
589 analysis based on the MD GWAS used in our work was reported in the original publication [32].

590  
591 The limitations of our study, including the precision of estimates and pathway analysis, can be  
592 attributed to the small sample size of the currently available MD GWAS data and the consequent low  
593 number of robustly associated genetic instruments. Despite using one of the largest MD GWAS  
594 cohorts to date (N=24,192) [32], the number of instruments was still relatively small (albeit higher  
595 than in earlier studies, such as [48], [59]). A summary table of all published MD GWAS studies is  
596 provided in a recent review [60]. A similarly sized MD GWAS conducted on data from the BCAC  
597 cohort (N=24,579-27,900) [61] has recently been released, but due to the unavailability of effect  
598 sizes, it is not possible to validate our findings using this resource. Once larger MD GWAS studies  
599 become available, and more SNPs with robust associations are identified, our results could be  
600 replicated. A higher number of instruments would also enable more informative clustering and  
601 pathway analyses, despite the likely maintained heterogeneity amongst individual estimates.  
602 Furthermore, the estimation of childhood body size indirect effect via MD would also likely be more  
603 precise.

604  
605 It is important to highlight a few recent developments in studying the genetics of mammographic  
606 density. Firstly, the first-ever GWAS of breast tissue structure patterns (also referred to as texture  
607 features) has recently been published [62], which is an emerging independent breast cancer risk  
608 factor [63]. Texture variation can differ substantially between women, despite having the same  
609 percent density. Including this trait in the MD phenotype analyses (including MR) can produce  
610 additional insights into the development of breast cancer. Secondly, as exploring proximal molecular  
611 mediators is becoming more widespread, the analysis of MD phenotypes in the BCAC cohort [61]  
612 also included a transcriptome-wide association study (TWAS). The study revealed additional novel  
613 associations between imputed breast tissue expression level and MD phenotypes. Some of the  
614 identified genes were located in proximity to GWAS loci, suggesting the observed genotype-  
615 phenotype association for MD may be mediated through gene expression. Further, a recent  
616 transcriptomic study [64] evaluating differentially expressed pathways in breast tissue samples from  
617 obese vs normal weight adolescents, identified inflammation-related genes as among the most highly  
618 activated upstream regulators in the obese breast tissue samples.

619  
620 Our study thoroughly explores the links between adiposity, puberty timing, and mammographic  
621 density, and breast cancer. The major finding of this study is that mammographic density, specifically  
622 dense area, potentially accounts for 56% of the protective effect of childhood adiposity on breast  
623 cancer. Understanding this mediating pathway is crucial since simply advocating for weight gain in  
624 childhood is clearly not a desirable goal. This finding is exciting because showing that adult MD is  
625 modifiable during the pubertal growth period means there could be opportunities to intervene during  
626 adolescence to reduce lifetime MD and associated breast cancer risk [18]. Further understanding of  
627 the underlying mechanism and biological pathways is required to explore potential avenues for  
628 intervention. In the study, we also showed that the density-increasing effect of later menarche may  
629 be due to lower adiposity in adolescence, which is associated with later puberty rather than an effect  
630 of age at menarche directly. The mechanisms linking childhood body size and age at menarche to  
631 breast cancer risk could therefore be entirely different and acting in opposing directions. Lastly, we  
632 found that genetic instruments for MD are heterogenous and pleiotropic, and there are likely several  
633 pathways underlying the role of mammographic density in influencing breast cancer risk. As MD  
634 GWAS sample sizes increase, this relationship can be further investigated, enhancing our  
635 understanding of the genetic basis of MD and its role in the aetiology of breast cancer.

636  
637  
638

## 639 **Methods**

640

### 641 **Data sources**

642

643 The mammographic density GWAS data used in this study is a meta-analysis of two studies (Hologic  
644 study, N=20,311 and GE study, N=3881; in total N=24,192) of non-Hispanic white women aged  
645 between 40-74 years from a larger population-based study, RPGEH (Research Program on Genes,  
646 Environment and Health), administered by Kaiser Permanente Northern California (KPNC) Division  
647 of Research [65], [66]. The cohort details and study design have been described previously in the  
648 original publication of this data [32]. Genotypes were re-imputed with an expanded reference panel,  
649 including the Haplotype Reference Consortium in addition to the 1000 Genomes Project Phase III  
650 data, to improve accuracy for less common variants. The GWAS analyses were adjusted for age at  
651 mammogram, BMI, genotype reagent kit, and the first ten principal components of ancestry as  
652 described previously [32]. Three mammographic density phenotypes were analysed: dense area  
653 (DA), non-dense area (NDA), and percent density (PD). The original MD GWAS published by Sieh  
654 *et al* in 2020 [32] was adjusted for BMI. For this study, the GWAS was rerun without this adjustment  
655 (“unadjusted GWAS”) on a slightly smaller subset of 24,158 women from the original cohort.

656

657 Childhood body size, adult body size, and age at menarche data used in this study were obtained  
658 from UK Biobank [67]. UK Biobank is a population-based health research resource consisting of  
659 approximately 500,000 people, aged between 40–69 years, who were recruited between the years  
660 2006 and 2010 from across the UK. The study design, participants and quality control (QC) methods  
661 have been described in detail previously [67]. The GWAS of childhood body size and adult body size  
662 used in this study were performed by Richardson *et al* [5] on UK Biobank data (N= 246,511; female-  
663 only data). Childhood body size is a categorical trait describing body size at age 10, with three  
664 categories (‘thinner than average’, ‘about average’, ‘plumper than average’), from a questionnaire  
665 completed by adult participants of UK Biobank. Adult body size measure was converted from  
666 continuous adult BMI in UK biobank into three groups based on the proportions of childhood body  
667 size data to ensure that the GWAS results of both measures are comparable [5]. The genetic scores  
668 for childhood and adult body size were independently validated in three separate cohorts (the HUNT  
669 study (Norway) [68], Young Finns Study [69], and ALSPAC (UK) [5]), which confirmed that the  
670 genetic instruments extracted by Richardson *et al* [5] can reliably separate childhood and adult body  
671 size as distinct exposures, in addition to being robust to differential measurement error in simulations  
672 performed in the original study. Age at menarche GWAS summary data (N=143,819) was accessed  
673 through OpenGWAS [70] ([gwas.mrcieu.ac.uk](https://gwas.mrcieu.ac.uk)) under ID *ukb-b-3768*.

674

675 The breast cancer data used in the study is from the Breast Cancer Association Consortium (BCAC)  
676 cohort of 2017 (N=228,951; overall sample and ER+/ER- samples, assessed from OpenGWAS  
677 under IDs: *ieu-a-1126*, *ieu-a-1127*, *ieu-a-1128*) [35] and the latest release of BCAC in 2020  
678 (N=247,173; overall sample and five molecular subtypes: Luminal A, Luminal B1, Luminal B2, HER2-  
679 enriched, and triple-negative breast cancer) [71] (details in Supplementary Table S1). The cohort  
680 design and genotyping protocol details are described elsewhere  
681 ([bcac.ccge.medschl.cam.ac.uk/bcac-groups/study-groups/](https://bcac.ccge.medschl.cam.ac.uk/bcac-groups/study-groups/),  
682 [bcac.ccge.medschl.cam.ac.uk/bcacdata/](https://bcac.ccge.medschl.cam.ac.uk/bcacdata/)). The study groups in the BCAC cohort do not include UK  
683 Biobank or MD GWAS cohorts. The overall sample results presented throughout the paper are for  
684 BCAC 2017 data. The results for BCAC 2020 overall sample are available in all relevant  
685 Supplementary tables, and are not shown here due to their similarity.

686

687

### 688 **Mendelian randomization**

689

690 Mendelian randomization (MR) is an application of instrumental variable analysis where genetic  
691 variants are used as instruments to estimate the causal relationship between a modifiable health  
692 exposure and a disease outcome [8] [9]. There are three core assumptions that genetic variants  
693 need to satisfy to qualify as valid instruments for the causal inference: (1) variants have to be reliably  
694 associated with exposure of interest, (2) there cannot be any confounders of the instrument and the

695 outcome, and (3) variants cannot be independently associated with the outcome, via pathway other  
696 than through the exposure (i.e. horizontal pleiotropy) [72].

697  
698 The analyses in this work were performed using the two-sample (univariable) MR approach, which  
699 relies on using GWAS summary statistics of two non-overlapping samples for exposure and outcome  
700 [73]. Two-sample MR analyses were performed using the inverse-variance weighted (IVW) method  
701 [74]. Alongside IVW, other complementary MR methods were applied to assess the robustness of  
702 the causal estimates and to overcome any potential violations of the MR assumptions (e.g. horizontal  
703 pleiotropy) (see **Sensitivity analysis** for further details).

704  
705 We used the two-step MR framework to assess whether an intermediate trait acts as a causal  
706 mediator between the exposure and the outcome of interest [75], [76]. Multivariable Mendelian  
707 randomization (MVMR) was used to estimate the independent direct effects of two traits together on  
708 the outcome [77] [78]. The genetic variants included in MVMR analysis have to be reliably associated  
709 with one or both exposures but not completely overlap (i.e. no perfect collinearity), and have to satisfy  
710 the MVMR-extended second and third assumptions of the standard MR analysis [46]. Diagnostic  
711 methods and sensitivity tests for the robustness of MVMR estimates [46] [79] are described under  
712 **Sensitivity analysis**.

713  
714 All analyses were conducted using R (v4.2.1). Univariable MR analyses and sensitivity tests were  
715 performed using the *TwoSampleMR* R package (v0.5.6) [80], which was also used for accessing  
716 GWAS summary data deposited in OpenGWAS [70] ([gwas.mrcieu.ac.uk](https://gwas.mrcieu.ac.uk)). Multivariable MR was  
717 carried out using the *MVMR* R package (version 0.2) [77].

718  
719 For all exposure traits, the instruments were extracted by selecting SNPs with p-value under the  
720  $5 \times 10^{-8}$  threshold and clumping the resulting set of variants with  $r^2 = 0.001$  using the default LD  
721 (linkage disequilibrium) reference panel in *TwoSampleMR* (1000 Genomes Project, European data  
722 only). When extracting instruments from the outcome (breast cancer) GWAS summary statistics,  
723 unavailable SNPs were substituted by proxies with a minimum LD  $r^2 = 0.8$ . The rest of the settings  
724 were kept to defaults as per the package version number. The number of instruments used in the  
725 analysis for all exposures: childhood body size (115), adult body size (173), age at menarche (190),  
726 dense area (21), non-dense area (8), percent density (11).

## 727 728 **Sensitivity analysis**

729  
730 In addition to the standard MR analysis (IVW), we used MR-Egger [43] and weighted median [44]  
731 MR methods to evaluate the validity of the analysed genetic instruments and to overcome and  
732 accommodate potential violations of the core MR assumptions. These complementary methods help  
733 to support the causal effects found with IVW, as a single method cannot account for all biological  
734 and statistical properties that may impact MR estimates. Also a variety of specialised tests were  
735 applied, as recommended in [80].

736  
737 To assess overall horizontal pleiotropy (violation of assumption 3), the intercept in the MR-Egger  
738 regression [43] was evaluated, and the heterogeneity among the genetic variants was quantified  
739 using Cochran's Q-statistic [45]. The intercept term in MR-Egger regression is a useful indication of  
740 whether directional horizontal pleiotropy is driving the results of an MR analysis, under the  
741 assumption that any pleiotropic effects are uncorrelated with the magnitude of the SNP exposure  
742 association. When the Egger intercept is close to zero (e.g.  $< 0.002$ ) and the P-value is large, this  
743 can be interpreted as no evidence of a substantial directional (horizontal) pleiotropic effect.

744  
745 When the Q-statistic for heterogeneity (difference in individual ratio estimates) is high and the  
746 corresponding p-value is small, this suggests evidence for heterogeneity and possibly horizontal  
747 pleiotropy. A high Q-statistic can also be used as an indicator of one or more variant outliers in the  
748 analysis, which may also violate the MR assumptions. In univariable MR, heterogeneity may be  
749 indicative of horizontal pleiotropy that does not act through one of the exposures. In MVMR,  
750 heterogeneity is quantified by  $Q_A$ -statistic (also a further modification of Cochran's Q), and small  $Q_A$   
751 indicates a lack of heterogeneity in the per-SNP effects [46].

752

753 We derived F-statistics in both univariable and MVMR to evaluate the instrument strength [81] [46],  
754 with  $F > 10$  indicating sufficient strength for minimal weak instrument bias in the analysis. We also  
755 evaluated the possibility of reverse causation via Steiger filtering and assessed whether each  
756 instrument explains more variance ( $R^2$ ) in the exposure rather than in the outcome [82].

757

758

### 759 **Additional sensitivity and outlier analyses**

760

761 To explore the excessive heterogeneity and potential pleiotropy identified in the effect of MD on  
762 breast cancer, we explored the genetic instruments using several outlier detection methods.

763

764 First, we applied MR-PRESSO [37], a method that detects overall pleiotropic bias through outlier  
765 detection by assessing each genetic variant's contribution to the overall heterogeneity. This method  
766 discards influential outliers from the IVW method and uses a distortion test to evaluate the  
767 significance of the distortion between the causal estimate before and after the removal of the outlier  
768 variants, providing an outlier-corrected pleiotropy-robust causal estimate as a result. The analysis  
769 was run using the *MR-PRESSO* R package (v1.0), using the default parameters.

770

771 We also used the approach implemented in *Radial-MR* [39] (R package v1.0) to identify outliers with  
772 the most weight in the MR analysis and the largest contribution to Cochran's Q statistic for  
773 heterogeneity. The analysis was conducted with a p-value threshold (*alpha* parameter) set to  
774 Bonferroni corrected for the number of SNPs tested in the analysis ( $p < 0.05/\text{number of instruments}$   
775 in the exposure) and using modified second-order weights (*weight* parameter).

776

777 Finally, to investigate the presence of clustered heterogeneity and assess the possibility of there  
778 being several distinct causal mechanisms by which MD may influence breast cancer risk, we  
779 performed clustered Mendelian randomization using *MR-Clust* [38] (R package v0.1.0). MR-Clust is  
780 a heterogeneity-based clustering algorithm that extends the typical MR assumption that a risk factor  
781 can influence an outcome via a single causal mechanism [83] to a framework that allows one or more  
782 mechanisms to be detected. The heterogeneity and outliers in the main MR result may indicate that  
783 different genetic variants influence the risk factor in distinct ways, e.g., via distinct biological  
784 mechanisms.

785

786 MR-Clust assigns variants to  $K$  clusters, where all variants have similar causal ratio estimates, a  
787 "null" cluster (variants with a null effect), and a "junk" cluster (non-null variants that do not fit into any  
788 of the  $K$  clusters). In our analysis, the clusters were formed of variants that had a great conditional  
789 probability of assignment (score  $> 0.9$ ), keeping the results conservative. Due to the limited number  
790 of instruments in MD exposure, we kept all clusters regardless of their size (visualised using the MR-  
791 Clust package built-in scatter plot).

792

793 The outliers identified by MR-PRESSO and Radial-MR analyses, as well as clusters of SNPs  
794 detected by MR-Clust, were displayed using single-SNP forest plots to explore individual SNPs  
795 heterogeneity. The single-SNP forest plots show the effect of the exposure on the outcome for each  
796 SNP separately (i.e. Wald ratio). The plots also included the IVW MR estimate with the identified  
797 outliers excluded, and the individual estimates for identified clusters.

798

### 799 **PheWAS**

800

801 To further examine the genetic instruments of the MD phenotypes and better understand the  
802 potential sources of effect heterogeneity, we performed a phenome-wide association study  
803 (PheWAS) analysis [40]. We used PhenoScanner V2 (*phenoscanner* R package v1.0) [84] [85] and  
804 OpenGWAS database ([gwas.mrcieu.ac.uk/phewas/](https://gwas.mrcieu.ac.uk/phewas/), accessed via *ieugwasr* R package v0.1.5) [70]  
805 to query publicly available GWAS data for associations with the SNPs from the MD phenotypes. The  
806 query was restricted to European ancestry datasets, retrieving SNP-trait associations of p-value  $< 5e$ -  
807 08.

808



809 We presented PheWAS results for each MD SNP grouped by clusters determined by the MR-Clust  
810 algorithm. This helped us to review the association differences between clusters of SNPs with the  
811 traits identified in GWAS databases, which might explain some of the observed heterogeneity in the  
812 MR results.

813  
814

### 815 **Gene and pathway exploration**

816

817 To explore the functional relevance of the identified clusters of MD instruments, we mapped  
818 instrument SNPs of each MD phenotype to genes and identified the pathways they are involved in.  
819 For gene mapping we used the SNP2Gene function of FUMA (the Functional Mapping and  
820 Annotation of GWAS) platform [86], where we used a 500-kb positional map, and included genes  
821 whose expression was associated with the locus in GTEx v8 (breast or adipose tissues). We  
822 extracted pathways using the *enrichR* R package (v3.1) [87] (including pathway definitions from  
823 Reactome, KEGG, GO terms, and WikiPathway databases). We also used the  
824 *ReactomeContentService4R* R package (v1.4.0) [88] to obtain more recent Reactome data  
825 (Reactome data in *enrichR* is only up until 2016). The pathway data was collected for a broader  
826 context only, and no formal gene-set overrepresentation analysis was performed.

827  
828

### 829 **Mediation analysis**

830

831 Mediation analysis is used to quantify the effects of an exposure on an outcome, which act directly  
832 or indirectly via an intermediate variable (i.e., mediator) [89]. Identifying mediators of the relationship  
833 between the exposure and the outcome enables intervention on those mediators to mitigate or  
834 strengthen the effects of the exposure [34].

835

836 The total effect of exposure on outcome includes both a direct effect and any indirect effects via one  
837 or more mediators. The total effect is captured by a standard univariable MR analysis. To decompose  
838 direct and indirect effects, we used the results from two-step MR and MVMR in two mediation  
839 analysis methods: Difference method and Product method.

840

841 For the Difference method, to estimate the indirect effect, we subtracted the direct effect of exposure  
842 on the outcome from MVMR (in analysis with the mediator) from the total effect of exposure on the  
843 outcome (univariable MR) [55]. In Product method (also known as 'product of coefficients'), the  
844 results from two steps of two-step MR analysis (i.e., the effect of exposure on the mediator and the  
845 effect of the mediator on the outcome) are multiplied to get the indirect effect [90], [75]. Here, we  
846 used the direct effect of the mediator on the outcome from MVMR as the second term in the  
847 calculation [89]. To estimate the standard error (SE) and later confidence intervals (CIs) of the  
848 indirect effect, we used 'Propagation of errors' approach for the Difference method estimate (as  
849 outlined in [55]) and Delta method (also known as Sobel test [91]) for the Product method estimate.  
850 Further details on performing mediation analysis are available in the Supplementary materials of our  
851 previous work [10]. The mediation analysis calculations are presented in **Supplementary Note 2**.

852

### 853 **Code availability**

854

855 All analyses in this study are available at: [https://github.com/mvab/mammographic\\_density\\_mr](https://github.com/mvab/mammographic_density_mr)

856

### 857 **Data availability**

858

859 The GWAS data for BCAC 2017 breast cancer (*ieu-a-1126*, *ieu-a-1127*, *ieu-a-1128*) and age at  
860 menarche (*ukb-b-3768*) was accessed from OpenGWAS (<https://gwas.mrcieu.ac.uk>). The BCAC 2020  
861 molecular subtype data is available at [https://bcac.ccge.medschl.cam.ac.uk/bcacdata/  
862 oncoarray/oncoarray-and-combined-summary-result/](https://bcac.ccge.medschl.cam.ac.uk/bcacdata/oncoarray/oncoarray-and-combined-summary-result/). Childhood and adult body size GWAS data was  
863 published in ref [5].

864



865 This study uses data from a GWAS of mammographic density (ref [32]). The RPGEH genotype data  
866 are available upon application to the KP Research Bank  
867 (<https://researchbank.kaiserpermanente.org/>). Additional relevant information is available from the  
868 authors upon reasonable request.

869

## 870 **Funding acknowledgements**

871

872 M.V. is supported by the University of Bristol Alumni Fund (Professor Sir Eric Thomas Scholarship).  
873 B.L.L. is supported by the University of Bristol Vice-Chancellor's fellowship, Academy of Medical  
874 Sciences, Elizabeth Blackwell Institute for Health Research (University of Bristol) and the Wellcome  
875 Trust Institutional Strategic Support Fund (ISSF3 (204813/Z/16/Z) and AMS (SBF003/1170)).  
876 M.V., G.D.S., E.S., T.G.R., R.C.R. work in the UK Medical Research Council Integrative Epidemiology  
877 Unit at the University of Bristol supported by Medical Research Council (MC\_UU\_00032/01,  
878 MC\_UU\_00032/03, MC\_UU\_00032/04). This work is also supported by a Cancer Research UK  
879 programme grant (the Integrative Cancer Epidemiology Programme) (C18281/A29019).  
880 W.S., L.A.H., J.H.R., S.E.A are supported by the U.S. National Institutes of Health (R01CA237541,  
881 R01CA264987, R01CA166827).

882

## 883 **Authors' contributions**

884

885 M.V., B.L.L., R.C.R., G.D.S., T.G.R., E.S. conceived and designed the study. M.V. performed the  
886 analyses, interpreted the results, and wrote the initial draft of the manuscript as well as subsequent drafts  
887 with critical input on results interpretation and manuscript revisions from E.S., B.L.L., T.G.R., G.D.S.,  
888 R.C.R., W.S., L.A.H., J.H.R., S.E.A. Access to mammographic density data was provided by W.S.,  
889 L.A.H., J.H.R., S.E.A.; J.H.R. performed genome-wide association studies of mammographic density  
890 phenotypes unadjusted for BMI.

891

892 The corresponding author attests that all listed authors meet authorship criteria and that no others meeting  
893 the criteria have been omitted. All authors read and approved the final manuscript.

894

895 We would also like to acknowledge Tom Gaunt and Tim Robinson for thoughtful project discussions.

896

897

898

## 899 **Competing interests**

900

901 T.G.R. is employed by GSK outside of this work, for unrelated research. All other authors declare no  
902 competing interests.

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

## 918 References

- 919
- 920 [1] H. Sung *et al.*, “Global cancer statistics 2020: GLOBOCAN estimates of incidence and  
921 mortality worldwide for 36 cancers in 185 countries,” *CA. Cancer J. Clin.*, vol. 0, no. 0, pp. 1–  
922 41, 2021.
- 923 [2] K. L. Britt, J. Cuzick, and K. A. Phillips, “Key steps for effective breast cancer prevention,”  
924 *Nature Reviews Cancer*, vol. 20, no. 8. Nature Publishing Group, pp. 417–436, 11-Jun-2020.
- 925 [3] H. J. Baer, S. S. Tworoger, S. E. Hankinson, and W. C. Willett, “Body fatness at young ages  
926 and risk of breast cancer throughout life,” *Am. J. Epidemiol.*, vol. 171, no. 11, pp. 1183–1194,  
927 2010.
- 928 [4] A. Furer *et al.*, “Adolescent obesity and midlife cancer risk: a population-based cohort study of  
929 2·3 million adolescents in Israel,” *Lancet Diabetes Endocrinol.*, vol. 8, no. 3, pp. 216–225,  
930 2020.
- 931 [5] T. G. Richardson, E. Sanderson, B. Elsworth, K. Tilling, and G. Davey Smith, “Use of genetic  
932 variation to separate the effects of early and later life adiposity on disease risk: Mendelian  
933 randomisation study,” *BMJ*, vol. 369, 2020.
- 934 [6] B. W. Jensen *et al.*, “Childhood body mass index trajectories, adult-onset type 2 diabetes, and  
935 obesity-related cancers,” *J. Natl. Cancer Inst.*, vol. 115, no. 1, pp. 43–51, Jan. 2023.
- 936 [7] Y. Hao *et al.*, “Reassessing the causal role of obesity in breast cancer susceptibility – a  
937 comprehensive multivariable Mendelian randomization investigating the distribution and timing  
938 of exposure,” *Int. J. Epidemiol.*, vol. 52, no. 1, p. 58, Jul. 2022.
- 939 [8] S. Ebrahim and G. Davey Smith, “Mendelian randomization: Can genetic epidemiology help  
940 redress the failures of observational epidemiology?,” *Int. J. Epidemiol.*, vol. 32, no. 1, pp. 1–22,  
941 Feb. 2003.
- 942 [9] E. Sanderson *et al.*, “Mendelian randomization,” *Nat. Rev. Methods Prim.*, vol. 2, no. 1, Dec.  
943 2022.
- 944 [10] M. Vabistsevits, G. Davey Smith, E. Sanderson, T. G. Richardson, B. Lloyd-Lewis, and R. C.  
945 Richmond, “Deciphering how early life adiposity influences breast cancer risk using Mendelian  
946 randomization,” *Commun. Biol.*, vol. 5, no. 1, 2022.
- 947 [11] N. F. Boyd *et al.*, “Heritable dense breasts & breast cancer,” vol. 6, no. October, pp. 798–808,  
948 2005.
- 949 [12] A. Pettersson *et al.*, “Mammographic density phenotypes and risk of breast cancer: a meta-  
950 analysis,” *J. Natl. Cancer Inst.*, vol. 106, no. 5, May 2014.
- 951 [13] K. A. Bertrand *et al.*, “Dense and nondense Mammographic area and risk of breast cancer by  
952 age and tumor characteristics,” *Cancer Epidemiol. Biomarkers Prev.*, vol. 24, no. 5, pp. 798–  
953 809, May 2015.
- 954 [14] V. A. McCormack and I. Dos Santos Silva, “Breast density and parenchymal patterns as  
955 markers of breast cancer risk: A meta-analysis,” *Cancer Epidemiol. Biomarkers Prev.*, vol. 15,  
956 no. 6, pp. 1159–1169, Jun. 2006.
- 957 [15] J. Stone *et al.*, “The heritability of mammographically dense and nondense breast tissue,”  
958 *Cancer Epidemiol. Biomarkers Prev.*, vol. 15, no. 4, pp. 612–617, Apr. 2006.
- 959 [16] G. Kleinstern *et al.*, “Association of mammographic density measures and breast cancer  
960 ‘intrinsic’ molecular subtypes,” vol. 187, pp. 215–224, 2021.
- 961 [17] M. S. Shawky, C. W. Huo, M. A. Henderson, A. Redfern, K. Britt, and E. W. Thompson, “A  
962 review of the influence of mammographic density on breast cancer clinical and pathological  
963 phenotype,” *Breast Cancer Res. Treat. 2019 1772*, vol. 177, no. 2, pp. 251–276, Jun. 2019.
- 964 [18] A. G. Ghadge, P. Dasari, J. Stone, E. W. Thompson, R. L. Robker, and W. V. Ingman,  
965 “Pubertal mammary gland development is a key determinant of adult mammographic density,”  
966 *Semin. Cell Dev. Biol.*, vol. 114, no. July, pp. 143–158, 2021.
- 967 [19] S. X. Sun *et al.*, “Breast physiology: Normal and abnormal development and function,” in *The*  
968 *Breast: Comprehensive Management of Benign and Malignant Diseases*, Elsevier, 2017, pp.  
969 37-56.e6.
- 970 [20] S. E. Alexeeff *et al.*, “Age at menarche and late adolescent adiposity associated with  
971 mammographic density on processed digital mammograms in 24,840 women,” *Cancer*  
972 *Epidemiol. Biomarkers Prev.*, vol. 26, no. 9, pp. 1450–1458, Sep. 2017.
- 973 [21] S. V. Ward *et al.*, “The association of age at menarche and adult height with mammographic  
974 density in the International Consortium of Mammographic Density,” *Breast Cancer Res.*, vol.  
975 24, no. 1, pp. 1–16, Dec. 2022.
- 976 [22] Collaborative Group on Hormonal Factors in Breast Cancer, “Menarche, menopause, and  
977 breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast

- 978 cancer from 117 epidemiological studies,” *Lancet Oncol.*, vol. 13, no. 11, pp. 1141–1151,  
979 2012.
- 980 [23] G. V. Dall and K. L. Britt, “Estrogen Effects on the Mammary Gland in Early and Late Life and  
981 Breast Cancer Risk,” *Front. Oncol.*, vol. 7, no. MAY, p. 1, May 2017.
- 982 [24] N. Brown *et al.*, “The relationship between breast size and anthropometric characteristics,”  
983 *Am. J. Hum. Biol.*, vol. 24, no. 2, pp. 158–164, Mar. 2012.
- 984 [25] M. B. Terry *et al.*, “Do Birth Weight and Weight Gain during Infancy and Early Childhood  
985 Explain Variation in Mammographic Density in Women in Midlife? Results from Cohort and  
986 Sibling Analyses,” *Am. J. Epidemiol.*, vol. 188, no. 2, pp. 294–304, 2019.
- 987 [26] F. Juul, V. W. Chang, P. Brar, and N. Parekh, “Birth weight, early life weight gain and age at  
988 menarche: a systematic review of longitudinal studies,” *Obes. Rev.*, vol. 18, no. 11, pp. 1272–  
989 1288, 2017.
- 990 [27] C. Prince, L. D. Howe, G. C. Sharp, A. Fraser, and R. C. Richmond, “Establishing the  
991 relationships between adiposity and reproductive factors: a multivariable Mendelian  
992 randomization analysis,” *medRxiv*, p. 2023.03.03.23286615, Mar. 2023.
- 993 [28] Z. J. Andersen, J. L. Baker, K. Bihmann, I. Vejborg, T. I. A. Sørensen, and E. Lynge, “Birth  
994 weight, childhood body mass index, and height in relation to mammographic density and  
995 breast cancer: A register-based cohort study,” *Breast Cancer Res.*, vol. 16, no. 1, pp. 1–11,  
996 Jan. 2014.
- 997 [29] J. L. Hopper *et al.*, “Childhood body mass index and adult mammographic density measures  
998 that predict breast cancer risk,” *Breast Cancer Res. Treat.*, vol. 156, no. 1, pp. 163–170, 2016.
- 999 [30] Y. Han *et al.*, “Adiposity Change Over the Life Course and Mammographic Breast Density in  
1000 Postmenopausal Women,” *Cancer Prev. Res.*, vol. 13, no. 5, pp. 475–482, 2020.
- 1001 [31] M. S. Rice *et al.*, “Mammographic density and breast cancer risk: A mediation analysis,”  
1002 *Breast Cancer Res.*, vol. 18, no. 1, p. 94, Sep. 2016.
- 1003 [32] W. Sieh *et al.*, “Identification of 31 loci for mammographic density phenotypes and their  
1004 associations with breast cancer risk,” *Nat. Commun.*, vol. 11, no. 1, Dec. 2020.
- 1005 [33] F. Chen *et al.*, “Mendelian randomization analyses of 23 known and suspected risk factors and  
1006 biomarkers for breast cancer overall and by molecular subtypes,” *Int. J. Cancer*, Apr. 2022.
- 1007 [34] E. Sanderson, “Multivariable Mendelian Randomization and Mediation,” *Cold Spring Harb.*  
1008 *Perspect. Med.*, 2020.
- 1009 [35] K. Michailidou *et al.*, “Association analysis identifies 65 new breast cancer risk loci,” 2017.
- 1010 [36] H. Zhang *et al.*, “Genome-wide association study identifies 32 novel breast cancer  
1011 susceptibility loci from overall and subtype-specific analyses,” *Nat. Genet.*, vol. 52, no. 6, pp.  
1012 572–581, Jun. 2020.
- 1013 [37] M. Verbanck, C. Y. Chen, B. Neale, and R. Do, “Detection of widespread horizontal pleiotropy  
1014 in causal relationships inferred from Mendelian randomization between complex traits and  
1015 diseases,” *Nat. Genet.* 2018 505, vol. 50, no. 5, pp. 693–698, Apr. 2018.
- 1016 [38] C. N. Foley, A. M. Mason, P. D. W. Kirk, and S. Burgess, “MR-Clust: Clustering of genetic  
1017 variants in Mendelian randomization with similar causal estimates,” *Bioinformatics*, vol. 37, no.  
1018 4, pp. 531–541, 2021.
- 1019 [39] J. Bowden *et al.*, “Improving the visualization, interpretation and analysis of two-sample  
1020 summary data Mendelian randomization via the Radial plot and Radial regression,” *Int. J.*  
1021 *Epidemiol.*, vol. 47, no. 4, pp. 1264–1278, Aug. 2018.
- 1022 [40] L. A. C. Millard, N. M. Davies, N. J. Timpson, K. Tilling, P. A. Flach, and G. Davey Smith, “MR-  
1023 PheWAS: Hypothesis prioritization among potential causal effects of body mass index on  
1024 many outcomes, using Mendelian randomization,” *Sci. Rep.*, vol. 5, no. 1, pp. 1–17, Nov.  
1025 2015.
- 1026 [41] V. W. Skrivankova *et al.*, “Strengthening the reporting of observational studies in epidemiology  
1027 using mendelian randomisation (STROBE-MR): explanation and elaboration,” *BMJ*, vol. 375,  
1028 Oct. 2021.
- 1029 [42] V. W. Skrivankova *et al.*, “Strengthening the Reporting of Observational Studies in  
1030 Epidemiology Using Mendelian Randomization: The STROBE-MR Statement,” *JAMA*, vol.  
1031 326, no. 16, pp. 1614–1621, Oct. 2021.
- 1032 [43] J. Bowden, G. Davey Smith, and S. Burgess, “Mendelian randomization with invalid  
1033 instruments: Effect estimation and bias detection through Egger regression,” *Int. J. Epidemiol.*,  
1034 vol. 44, no. 2, pp. 512–525, May 2015.
- 1035 [44] J. Bowden, G. Davey Smith, P. C. Haycock, and S. Burgess, “Consistent Estimation in  
1036 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median  
1037 Estimator,” *Genet. Epidemiol.*, vol. 40, no. 4, pp. 304–314, May 2016.

- 1038 [45] J. Bowden *et al.*, “Improving the accuracy of two-sample summary-data Mendelian  
1039 randomization: Moving beyond the NOME assumption,” *Int. J. Epidemiol.*, vol. 48, no. 3, pp.  
1040 728–742, 2019.
- 1041 [46] E. Sanderson, W. Spiller, and J. Bowden, “Testing and correcting for weak and pleiotropic  
1042 instruments in two-sample multivariable Mendelian randomization,” *Stat. Med.*, vol. 40, no. 25,  
1043 pp. 5434–5452, Apr. 2021.
- 1044 [47] J. Yarmolinsky *et al.*, “Causal inference in cancer epidemiology: What is the role of mendelian  
1045 randomization?,” *Cancer Epidemiology Biomarkers and Prevention*, vol. 27, no. 9. American  
1046 Association for Cancer Research Inc., pp. 995–1010, 01-Sep-2018.
- 1047 [48] S. Lindström *et al.*, “Genome-wide association study identifies multiple loci associated with  
1048 both mammographic density and breast cancer risk,” *Nat. Commun.*, vol. 5, p. 5303, Oct.  
1049 2014.
- 1050 [49] P. Fernandez-Navarro *et al.*, “Genome wide association study identifies a novel putative  
1051 mammographic density locus at 1q12-q21,” *Int. J. Cancer*, vol. 136, no. 10, pp. 2427–2436,  
1052 May 2015.
- 1053 [50] N. Eriksson *et al.*, “Genetic variants associated with breast size also influence breast cancer  
1054 risk,” *BMC Med. Genet.*, vol. 13, Jun. 2012.
- 1055 [51] M. J. Sherratt, J. C. McConnell, and C. H. Streuli, “Raised mammographic density: Causative  
1056 mechanisms and biological consequences,” *Breast Cancer Res.*, vol. 18, no. 1, pp. 1–9, May  
1057 2016.
- 1058 [52] N. F. Boyd, L. J. Martin, M. J. Yaffe, and S. Minkin, “Mammographic density and breast cancer  
1059 risk: current understanding and future prospects,” *Breast Cancer Res.*, vol. 13, no. 6, Nov.  
1060 2011.
- 1061 [53] F. P. Hartwig, K. Tilling, G. Davey Smith, D. A. Lawlor, and M. C. Borges, “Bias in two-sample  
1062 Mendelian randomization when using heritable covariable-adjusted summary associations,”  
1063 *Int. J. Epidemiol.*, vol. 50, no. 5, pp. 1639–1650, 2021.
- 1064 [54] J. Gilbody, M. C. Borges, G. Davey Smith, and E. Sanderson, “Multivariable MR can mitigate  
1065 bias in two-sample MR using covariable-adjusted summary associations,” *medRxiv*, p.  
1066 2022.07.19.22277803, Jul. 2022.
- 1067 [55] S. Burgess, D. J. Thompson, J. M. B. Rees, F. R. Day, J. R. Perry, and K. K. Ong, “Dissecting  
1068 causal pathways using mendelian randomization with summarized genetic data: Application to  
1069 age at menarche and risk of breast cancer,” *Genetics*, vol. 207, no. 2, pp. 481–487, Oct. 2017.
- 1070 [56] A. Balmain, “Peto’s paradox revisited: black box vs mechanistic approaches to understanding  
1071 the roles of mutations and promoting factors in cancer,” *Eur. J. Epidemiol.*, vol. 1, pp. 1–8,  
1072 Dec. 2022.
- 1073 [57] M. Archer, P. Dasari, A. Evdokiou, and W. V. Ingman, “Biological mechanisms and therapeutic  
1074 opportunities in mammographic density and breast cancer risk,” *Cancers (Basel)*, vol. 13, no.  
1075 21, pp. 1–21, 2021.
- 1076 [58] W. Wang *et al.*, “Clustered Mendelian randomization analyses identify distinct and opposing  
1077 pathways in the association between genetically influenced insulin-like growth factor-1 and  
1078 type 2 diabetes mellitus,” *Int. J. Epidemiol.*, vol. 51, no. 6, pp. 1874–1885, Jun. 2022.
- 1079 [59] J. S. Brand, K. Humphreys, J. Li, R. Karlsson, P. Hall, and K. Czene, “Common genetic  
1080 variation and novel loci associated with volumetric mammographic density,” *Breast Cancer  
1081 Res.*, vol. 20, no. 1, Apr. 2018.
- 1082 [60] A. Khorshid Shamshiri, M. Alidoust, M. Hemmati Nokandei, A. Pasdar, and F. Afzaljavan,  
1083 “Genetic architecture of mammographic density as a risk factor for breast cancer: a systematic  
1084 review,” *Clin. Transl. Oncol.* 2023, pp. 1–19, Jan. 2023.
- 1085 [61] H. Chen *et al.*, “Genome-wide and transcriptome-wide association studies of mammographic  
1086 density phenotypes reveal novel loci,” *Daniel S. McConnell*, vol. 21, no. 1, p. 27, Dec. 2022.
- 1087 [62] Y. Liu *et al.*, “A genome-wide association study of mammographic texture variation,” *Breast  
1088 Cancer Res.* 2022 241, vol. 24, no. 1, pp. 1–15, Nov. 2022.
- 1089 [63] E. T. Warner *et al.*, “Automated percent mammographic density, mammographic texture  
1090 variation, and risk of breast cancer: a nested case-control study,” *NPJ breast cancer*, vol. 7,  
1091 no. 1, Dec. 2021.
- 1092 [64] A. Burkholder *et al.*, “Investigation of the adolescent female breast transcriptome and the  
1093 impact of obesity,” *Breast Cancer Res.*, vol. 22, no. 1, pp. 1–14, 2020.
- 1094 [65] Y. Banda *et al.*, “Characterizing race/ethnicity and genetic ancestry for 100,000 subjects in the  
1095 genetic epidemiology research on adult health and aging (GERA) cohort,” *Genetics*, vol. 200,  
1096 no. 4, pp. 1285–1295, Aug. 2015.
- 1097 [66] M. N. Kvale *et al.*, “Genotyping informatics and quality control for 100,000 subjects in the



- 1098 genetic epidemiology research on adult health and aging (GERA) cohort," *Genetics*, vol. 200,  
1099 no. 4, pp. 1051–1060, Aug. 2015.
- 1100 [67] C. Sudlow *et al.*, "UK Biobank: An Open Access Resource for Identifying the Causes of a Wide  
1101 Range of Complex Diseases of Middle and Old Age," *PLoS Med.*, vol. 12, no. 3, Mar. 2015.
- 1102 [68] M. Brandkvist *et al.*, "Separating the genetics of childhood and adult obesity: a validation study  
1103 of genetic scores for body mass index in adolescence and adulthood in the HUNT Study,"  
1104 *Hum. Mol. Genet.*, vol. 29, no. 24, pp. 3966–3973, Dec. 2020.
- 1105 [69] T. G. Richardson *et al.*, "Evaluating the direct effects of childhood adiposity on adult systemic  
1106 metabolism: a multivariable Mendelian randomization analysis," *Int. J. Epidemiol.*, Mar. 2021.
- 1107 [70] B. Elsworth *et al.*, *The MRC IEU OpenGWAS data infrastructure*. 2020, p. 2020.08.10.244293.
- 1108 [71] H. Zhang *et al.*, "Genome-wide association study identifies 32 novel breast cancer  
1109 susceptibility loci from overall and subtype-specific analyses," *Nat. Genet.*
- 1110 [72] D. A. Lawlor, R. M. Harbord, J. A. C. Sterne, N. Timpson, and G. Davey Smith, "Mendelian  
1111 randomization: Using genes as instruments for making causal inferences in epidemiology,"  
1112 *Stat. Med.*, vol. 27, no. 8, pp. 1133–1163, Apr. 2008.
- 1113 [73] S. Burgess, R. A. Scott, N. J. Timpson, G. Davey Smith, and S. G. Thompson, "Using  
1114 published data in Mendelian randomization: A blueprint for efficient identification of causal risk  
1115 factors," *Eur. J. Epidemiol.*, vol. 30, no. 7, pp. 543–552, Jul. 2015.
- 1116 [74] S. Burgess, A. Butterworth, and S. G. Thompson, "Mendelian randomization analysis with  
1117 multiple genetic variants using summarized data," *Genet. Epidemiol.*, vol. 37, no. 7, pp. 658–  
1118 665, Nov. 2013.
- 1119 [75] C. L. Relton and G. Davey Smith, "Two-step epigenetic mendelian randomization: A strategy  
1120 for establishing the causal role of epigenetic processes in pathways to disease," *Int. J.*  
1121 *Epidemiol.*, vol. 41, no. 1, pp. 161–176, 2012.
- 1122 [76] J. Zheng *et al.*, "Recent Developments in Mendelian Randomization Studies," *Curr. Epidemiol.*  
1123 *Reports*, vol. 4, no. 4, pp. 330–345, 2017.
- 1124 [77] E. Sanderson, G. Davey Smith, F. Windmeijer, and J. Bowden, "An examination of  
1125 multivariable Mendelian randomization in the single-sample and two-sample summary data  
1126 settings," *Int. J. Epidemiol.*, vol. 48, no. 3, pp. 713–727, Jun. 2019.
- 1127 [78] S. Burgess and S. G. Thompson, "Multivariable Mendelian randomization: The use of  
1128 pleiotropic genetic variants to estimate causal effects," *Am. J. Epidemiol.*, vol. 181, no. 4, pp.  
1129 251–260, 2015.
- 1130 [79] J. M. B. Rees, A. M. Wood, and S. Burgess, "Extending the MR-Egger method for  
1131 multivariable Mendelian randomization to correct for both measured and unmeasured  
1132 pleiotropy," *Stat. Med.*, vol. 36, no. 29, pp. 4705–4718, Dec. 2017.
- 1133 [80] G. Hemani *et al.*, "The MR-base platform supports systematic causal inference across the  
1134 human phenome," *Elife*, vol. 7, May 2018.
- 1135 [81] S. Burgess and S. G. Thompson, "Avoiding bias from weak instruments in Mendelian  
1136 randomization studies," *Int. J. Epidemiol.*, vol. 40, no. 3, pp. 755–764, Jun. 2011.
- 1137 [82] G. Hemani, K. Tilling, and G. Davey Smith, "Orienting the causal relationship between  
1138 imprecisely measured traits using GWAS summary data," *PLoS Genet.*, vol. 13, no. 11, pp. 1–  
1139 22, 2017.
- 1140 [83] S. Burgess, C. N. Foley, and V. Zuber, "Inferring causal relationships between risk factors and  
1141 outcomes using genetic variation," *Handb. Stat. Genomics*, vol. 1, pp. 651–677, 2019.
- 1142 [84] M. A. Kamat *et al.*, "PhenoScanner V2: an expanded tool for searching human genotype-  
1143 phenotype associations," *Bioinformatics*, vol. 35, no. 22, pp. 4851–4853, Nov. 2019.
- 1144 [85] J. R. Staley *et al.*, "PhenoScanner: a database of human genotype-phenotype associations,"  
1145 *Bioinformatics*, vol. 32, no. 20, pp. 3207–3209, Oct. 2016.
- 1146 [86] K. Watanabe, E. Taskesen, A. Van Bochoven, and D. Posthuma, "Functional mapping and  
1147 annotation of genetic associations with FUMA," *Nat. Commun.*, vol. 8, no. 1, Dec. 2017.
- 1148 [87] M. V. Kuleshov *et al.*, "Enrichr: a comprehensive gene set enrichment analysis web server  
1149 2016 update," *Nucleic Acids Res.*, vol. 44, no. W1, pp. W90–W97, 2016.
- 1150 [88] C.-L. Poon, "ReactomeContentService4R: Interface for the Reactome Content Service [R  
1151 package]." 2022.
- 1152 [89] A. R. Carter *et al.*, "Mendelian randomisation for mediation analysis: Current methods and  
1153 challenges for implementation," *European Journal of Epidemiology*. 2021.
- 1154 [90] S. Burgess, R. M. Daniel, A. S. Butterworth, and S. G. Thompson, "Network Mendelian  
1155 randomization: Using genetic variants as instrumental variables to investigate mediation in  
1156 causal pathways," *Int. J. Epidemiol.*, vol. 44, no. 2, pp. 484–495, 2015.
- 1157 [91] M. E. Sobel, "Asymptotic Confidence Intervals for Indirect Effects in Structural Equation



1158 Models," *Sociol. Methodol.*, vol. 13, pp. 290–312, 1982.  
1159  
1160  
1161  
1162  
1163  
1164